{
    "clinical_study": {
        "@rank": "107542", 
        "arm_group": [
            {
                "arm_group_label": "Paclitaxel-coated balloon", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon."
            }, 
            {
                "arm_group_label": "Bare balloon", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, randomized, multi-center, single-blind study to demonstrate the\n      safety and effectiveness of the CVI Paclitaxel-coated percutaneous transluminal angioplasty\n      (PTA) balloon versus bare PTA balloon for the treatment of patients with de novo\n      occluded/stenotic or reoccluded/restenotic lesions of the superficial femoral (SFA) and\n      popliteal arteries."
        }, 
        "brief_title": "CVI Drug Coated Balloon European Randomized Clinical Trial", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peripheral Arterial Disease", 
            "Claudication"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic leg ischemia requiring treatment of the superficial femoral or popliteal\n             arteries\n\n          -  Rutherford clinical category 2, 3 or 4\n\n          -  Male or non-pregnant female at least 18 years\n\n        Exclusion Criteria:\n\n          -  Co-existing clinically significant aneurismal disease of the abdominal aorta, iliac\n             or popliteal arteries\n\n          -  Significant gastrointestinal bleeding or any coagulopathy that would contraindicate\n             the use of anti-platelet therapy\n\n          -  Known intolerance of study medications, paclitaxel or contrast agent\n\n          -  Active participation in another investigational device or drug study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858363", 
            "org_study_id": "TP 1360"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paclitaxel-coated balloon", 
                "intervention_name": "CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Bare balloon", 
                "intervention_name": "Bare Percutaneous Transluminal Angioplasty Balloon Catheter", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Peripheral arterial disease", 
            "claudication", 
            "drug-coated balloon", 
            "drug-eluting balloon"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "Center for Diagnostic Radiology and Minimally Invasive Therapy"
            }, 
            "investigator": {
                "last_name": "Henrik Schroeder, M.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Randomized, Multi-center, Single-blinded Study for the Treatment of Subjects Presenting With De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using Paclitaxel or Bare Percutaneous Transluminal Angioplasty Balloon Catheter", 
        "overall_contact": {
            "email": "amaelle.vuillaume@covidien.com", 
            "last_name": "Ama\u00eblle Vuillaume"
        }, 
        "overall_official": {
            "affiliation": "Center for Diagnostic Radiology & Minimally Invasive Therapy, The Jewish Hospital", 
            "last_name": "Henrik Schroeder, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Austria: Austrian Medicines and Medical Devices Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Primary Patency at 12 months post-procedure", 
                "measure": "Primary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Freedom from device and procedure related target limb major amputation or death through 30-days post-procedure and clinically-driven target lesion revascularization at 12-month", 
                "measure": "Primary Safety Endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "30-Days and 12-Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858363"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Covidien", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Covidien", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}